Matrixyl vs PTD-DBM
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Palmitoyl Pentapeptide-4, Pal-KTTKS
Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Matrixyl (Limited Research).
Detailed Comparison
| Attribute | Matrixyl | PTD-DBM |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | KTTKS is a five-amino-acid piece of type I collagen. When collagen breaks down, fragments like this are released, and the skin reads them as a signal that the matrix needs repair, which prompts fibroblasts to make more collagen and other support proteins, a process called matrikine signaling. Matrixyl essentially feeds the skin that repair signal on purpose. The palmitoyl (fatty acid) tail is bolted on to make the otherwise water-loving peptide lipophilic enough to penetrate the outer skin layer, which is the part that actually lets a topical work. | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. |
| Common Dosing | Limited community data available See research protocols | No official dose. Sold as 1 mg or 5 mg vials, or a ready-made ~0.001% topical spray Once daily to the scalp in most community routines |
| Administration | Topical (serums, creams) | Topical (applied to skin) in published research; usually co-applied with valproic acid |
| Typical Duration | 8-12 weeks for visible results, ongoing use | Applied over several weeks in animal studies |
| Best Time to Take | Morning or as directed | Not established (topical in animal studies) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Matrixyl has the kind of human data most cosmetic peptides lack. The pivotal Robinson 2005 study in the International Journal of Cosmetic Science was a 12-week, double-blind, placebo-controlled, split-face trial in 93 women aged 35 to 55, comparing a moisturizer with 3 ppm Pal-KTTKS against the same moisturizer alone, and it found significant reductions in wrinkles and fine lines on the peptide side, with good tolerability. Cell and lab studies support the mechanism, showing increased synthesis of collagen I and IV and fibronectin. The frequently quoted figures like 117 percent collagen increase or 68 percent wrinkle reduction come largely from manufacturer in vitro and formulation data, so treat the exact percentages skeptically even though the direction of effect is real. Overall this is a well-tolerated peptide with genuine, if modest, controlled human evidence for texture and fine lines, and it does not require injection. It will not erase deep dynamic wrinkles the way muscle-targeting treatments aim to. | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a combination of 2 mM PTD-DBM and 500 mM valproic acid outperformed 100 mM minoxidil in that model (mM means millimolar, which describes how concentrated the topical liquid was, not a milligram dose). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. |
Frequently Asked Questions: Matrixyl vs PTD-DBM
What is the difference between Matrixyl and PTD-DBM?
Matrixyl is a skin & hair peptide that matrixyl is the trade name (sederma) for palmitoyl pentapeptide-4, also written pal-kttks, a collagen-fragment peptide attached to a fatty acid so it can cross skin. unlike botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. it is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof. PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Matrixyl or PTD-DBM?
Neither is universally "better" - the choice depends on your specific goals. Matrixyl is typically used for skin & hair purposes, while PTD-DBM is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Matrixyl and PTD-DBM be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Matrixyl and PTD-DBM together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.